Radia, D., & Reiter, A. (2022). Corrigendum to ‘MPN-395: efficacy and safety of ≤200 mg avapritinib in patients with advanced systemic mastocytosis : pooled results from the phase 1 EXPLORER and interim phase 2 PATHFINDER studies’ [Clinical Lymphoma Myeloma & Leukemia 21S1 (2021) S367-S368]: Corrigendum. Clinical lymphoma, myeloma & leukemia, 22(4), . https://doi.org/10.1016/j.clml.2021.12.002
Chicago-Zitierstil (17. Ausg.)Radia, Deepti, und Andreas Reiter. "Corrigendum to ‘MPN-395: Efficacy and Safety of ≤200 Mg Avapritinib in Patients with Advanced Systemic Mastocytosis : Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies’ [Clinical Lymphoma Myeloma & Leukemia 21S1 (2021) S367-S368]: Corrigendum." Clinical Lymphoma, Myeloma & Leukemia 22, no. 4 (2022). https://doi.org/10.1016/j.clml.2021.12.002.
MLA-Zitierstil (9. Ausg.)Radia, Deepti, und Andreas Reiter. "Corrigendum to ‘MPN-395: Efficacy and Safety of ≤200 Mg Avapritinib in Patients with Advanced Systemic Mastocytosis : Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies’ [Clinical Lymphoma Myeloma & Leukemia 21S1 (2021) S367-S368]: Corrigendum." Clinical Lymphoma, Myeloma & Leukemia, vol. 22, no. 4, 2022, https://doi.org/10.1016/j.clml.2021.12.002.